Skip to
  1. Homepage
  2. Rare diseases
  3. Search
Simple search

Simple search

*
(*) mandatory field





 

Other search option(s)

Alkaptonuria

ORPHA56
Synonym(s) Hereditary ochronosis
Homogentisic acid oxidase deficiency
Prevalence 1-9 / 1 000 000
Inheritance Autosomal recessive
Age of onset Adult
Infancy
ICD-10
  • E70.2
OMIM
UMLS
  • C0002066
  • C2931645
MeSH
  • C537862
  • D000474
MedDRA
  • 10001689

Summary

Disease definition

Alkaptonuria is a metabolic disease characterized by the accumulation of homogentisic acid (HGA) and its oxidized product, benzoquinone acetic acid (BQA), in various tissues (e.g. cartilage, connective tissue) and body fluids (urine, sweat), causing urine to darken when exposed to air as well as grey-blue coloration of the sclera and ear helix (ochronosis), and a disabling joint disease involving both the axial and peripheral joints (ochronotic arthropathy).

Epidemiology

Worldwide birth prevalence is estimated at around 1/111,000-1/1,000,000.

Clinical description

Many affected individuals are asymptomatic and unaware of their condition until adulthood, however, homogentisic aciduria may be recognized early in infancy by dark-stained diapers. After the third decade, unusual pigmentation of the sclera and the skin overlying cartilage begins to be observed, as well as muscular-skeletal symptoms such as back pain and stiffness. Involvement of the large peripheral joints usually occurs several years after spinal changes, often leading to end-stage joint disease. Ochronotic peripheral arthropathy is generally degenerative in nature. From the fourth decade, joint mobility diminishes. Ankylosis may be present. Fractures of the vertebrae and long bones are also possible. Other features may include genitourinary (e.g. renal, bladder, prostatic stones) and cardiac (mitral valvulitis, arrhythmias) complications as well as respiratory insufficiency due to musculoskeletal involvement.

Etiology

Patients are homozygous or compound heterozygous for loss-of-function mutations (more than 120 different variants described worldwide) in the HGD gene (3q), encoding homogentisate 1,2-dioxygenase, an enzyme of the phenylalanine and tyrosine catabolic pathway. The inability to break down HGA leads to its accumulation. Tissue damage results from the deposition of a melanin-like pigment, which is a polymerised form of BQA, that has a high affinity for connective tissue. This pigment is able to trigger numerous redox reactions and induce free radical production, causing further damage to the connective tissue.

Diagnostic methods

Diagnosis is suspected upon clinical examination and is based on the amount of HGA found in the urine using gas chromatography-mass spectroscopy. As many patients present without dark urine, it may be advisable to look for HGA in all patients with radiographic evidence of osteoarthritis. A spinal x-ray will reveal disk degeneration combined with dense calcification, particularly in the lumbar area. Genetic testing confirms the diagnosis.

Differential diagnosis

Differential diagnosis includes acute intermittent porphyria, rheumatoid arthritis, ankylosing spondylitis (see these terms) and osteoarthritis.

Genetic counseling

Transmission is autosomal recessive. Family members should be referred for genetic counseling.

Management and treatment

Treatment is palliative. Dietary restriction (low protein diet) is beneficial, but compliance is often limited. Medical therapy (paracetamol, non-steroidal anti-inflammatory drugs) associated with physiotherapy help to minimize pain and improve the range of joint motion. Older individuals may require removal and fusion of lumbar discs. Hip or knee joint replacement may be necessary. Therapeutic strategies aimed at perturbing the altered phenylalanine-tyrosine pathway have been devised (e.g. nitisinone). However, the long-term effectiveness and safety of this drug has yet to be established. Other possible approaches are aimed at exploring the effects of antioxidant biomolecules in preventing the conversion of HGA to BQA (e.g., N-acetylcysteine). However, previous attempts with vitamin C have proven to be unsatisfactory.

Prognosis

Life expectancy is not significantly reduced but pain can be constant and progressive functional decline is observed with a loss of mobility; patients often require the use of physical aids (crutches, wheelchair). Cardiac complications are often life-threating and may worsen the prognosis.

Expert reviewer(s)

  • Pr Berardino PORFIRIO

(*) Required fields.

Attention: Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.


Captcha image

Detailed information

Summary information
Anesthesia guidelines
Review article
Article for general public
Clinical genetics review
Get Acrobat Reader
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.